Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

June 01, 2008 (Vol. 28, No. 11)

Superbugs vs. Superdrugs: Race Goes On

Development of Antibacterial Therapies Needs to Take a Front-Row Seat in the Research Arena

  • At the recent “Superbugs and Superdrugs” conference in London, Nora Kaarela, CEO of Ipsat Therapies (www.ipsat-ther.com), commented, “Hospital-acquired bacterial infections are a leading cause of death in the U.S., and it costs between $16,000 and $100,000 per patient to treat this largely preventable problem.” Despite the alarming rise ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.